Market Performance - The Hong Kong stock market opened high but experienced fluctuations, closing with the Hang Seng Index down 0.11% at 25,774.14 points, the Hang Seng Tech Index down 0.69% at 5,488.89 points, the National Enterprises Index down 0.29% at 8,913.83 points, and the Red Chip Index down 0.19% at 4,067.53 points [1] Sector Performance - Large tech stocks showed mixed performance: Alibaba rose 0.55%, Tencent fell 2.03%, JD.com increased by 0.45%, Xiaomi dropped 1.51%, NetEase decreased by 0.65%, Meituan rose 0.39%, Kuaishou fell 3.52%, and Bilibili decreased by 0.05% [1] - Gold stocks continued to rise, with WanGuo Gold Group up over 5%, Shandong Gold up over 4%, and Zhaojin Mining up over 2% [1] - Wind power stocks led gains, with Dongfang Electric up over 8% [1] - Biotech stocks declined, with Yaojie Ankang down over 18% [1] - Chinese brokerage stocks opened high but closed lower, with Dongfang Securities down over 1% [1] Company News - Cathay Pacific reported 2.5304 million passengers in November, a year-on-year increase of 26% [2] - Shandong High New Energy's subsidiary signed an EPC contract worth RMB 405.5 million [2] - China General Nuclear Power's units are in testing, with adjusted operational timelines for 2026 [2] - Lehua Entertainment signed a business cooperation framework agreement with Youku [3] - Dipo Technology entered a strategic cooperation agreement with Muxi Co., focusing on enterprise-level AI applications [4] - Nanshan Aluminum's alumina design capacity has been increased to 4 million tons [7] Institutional Insights - Huatai Securities noted that the market is still in a left-side layout phase, with supply and demand pressures expected to persist into the year-end [10] - Guotou Securities highlighted the historical strength of U.S. stocks at year-end, despite uncertainties regarding interest rates and inflation paths for 2026 [10] - Galaxy Securities recommended focusing on the tech sector as a long-term investment theme, anticipating a rebound due to multiple favorable factors [10]

本文源自：金融界AI电报 圣诺医药-B(02257.HK)发布公告，公司全资附属公司Sirnaomics, Inc.已完成试验药物STP707的I期试验， 并已向美国食品药品监督管理局(FDA)正式提交临床研究报告。 ...

Core Viewpoint - Sanofi's subsidiary, Sirnaomics, Inc., has completed the Phase I trial of the investigational drug STP707 and has formally submitted the clinical research report to the FDA [1] Group 1: Clinical Trial Details - The Phase I trial included adults with advanced, metastatic, or unresectable solid tumors that had progressed or were unresponsive to standard treatments [1] - STP707 demonstrated clinical activity in these patients, with some achieving disease stabilization and delaying disease progression in a population with limited treatment options [1] - Patients received different doses of STP707 via intravenous administration, with most side effects being manageable [1] Group 2: Regulatory and Development Plans - The completion of the Phase I trial and submission of the clinical research report is considered a key milestone for STP707 [1] - Following the submission, Sirnaomics, Inc. is preparing to initiate discussions with the FDA to determine the strategy for Phase II development [1]

公司相信，完成I期试验并向FDA提交临床研究报告乃STP707的一个关键里程碑。随着临床研究报告的 提交，Sirnaomics,Inc.准备在STP707I期试验提交完成的基础上，与FDA启动讨论，以确定II期开发策 略。 圣诺医药-B(02257)发布公告，公司全资附属公司Sirnaomics,Inc.已完成试验药物STP707的I期试验，并已 向美国食品药品监督管理局(FDA)正式提交临床研究报告。 该研究纳入患有晚期、转移性或无法手术的实体瘤的成年人，该等实体瘤已经扩散或无法通过手术切 除，且其癌症对标准治疗已停止反应。STP707在该等患者中展示出确切的临床活性，部分患者疾病实 现稳定，在治疗选择有限且经过多线既往治疗的群体中延缓了疾病进展。该等患者透过静脉给药方式接 受了不同剂量的STP707。此早期阶段的结论为，STP707可以多种剂量给药，副作用大多可控。 ...

Core Viewpoint - The article discusses the significant organizational changes and strategic shifts at Huaxi Biological, particularly focusing on the recent layoffs and the company's investment in Saint Nor Pharmaceutical, indicating a transition from a "traffic empire" to a "technology engine" in the biopharmaceutical sector [3][4][5]. Group 1: Layoff Turmoil - Huaxi Biological has undergone substantial layoffs and internal investigations, with teams like "Muscle Vitality" and "Mibelle" shrinking from over a hundred to just a few members, and compensation standards set at N+1 [4][6]. - CEO Zhao Yan has initiated a "clean-up" campaign, emphasizing zero tolerance for corruption and restructuring the company's power dynamics, leading to significant turnover in the executive team [4][5]. - The layoffs have created organizational instability, risking knowledge leakage and hindering product development and market responsiveness [6]. Group 2: Shift to Small Nucleic Acids - Huaxi Biological has invested approximately HKD 139 million to acquire a 9.44% stake in Saint Nor Pharmaceutical, aiming to leverage its RNA interference technology for weight loss treatments [8][9]. - Saint Nor is recognized as the first small nucleic acid drug company listed in the Asia-Pacific region, with a robust pipeline targeting various diseases, including cancer and metabolic disorders [9][10]. - The investment is seen as a strategic move to enter the innovative drug sector, with Huaxi planning to collaborate on clinical and commercial efforts for the STP705 targeted weight loss project [11]. Group 3: The Weight Loss Drug Market - The weight loss drug market is projected to grow significantly, with estimates suggesting it could reach CNY 800-1000 billion by 2030, capturing over one-third of the global market share [13][14]. - The increasing prevalence of obesity in China, with over 200 million individuals classified as obese, presents a substantial market opportunity for weight loss solutions [13]. - Regulatory support and advancements in drug technology are expected to facilitate market entry for new weight loss drugs, enhancing the competitive landscape [12][14]. Group 4: Future Market Dynamics - The article highlights the potential for the weight loss drug market to evolve into a comprehensive metabolic management ecosystem, integrating various therapeutic approaches and technologies [16]. - By 2035, advancements in drug delivery and treatment methodologies could significantly expand the market, with the potential for annual customer value to increase from CNY 10,000 to CNY 50,000 [16]. - The narrative emphasizes the need for stakeholders to view the weight loss drug market as part of a larger metabolic revolution, rather than merely a series of individual product launches [16].

Group 1 - The stock of Sanofi Pharmaceuticals-B (02257) increased by over 17% during trading, with a current rise of 15.84% to HKD 11.85, and a trading volume of HKD 15.0443 million [1] - Sanofi Pharmaceuticals-B reported a significant decline in other income, which amounted to USD 12.4 thousand, a year-on-year decrease of 87.4%. The company recorded a loss attributable to shareholders of USD 3.698 million, which represents a year-on-year narrowing of 91% [1] - The reduction in losses is attributed to several factors, including a decrease in fair value losses on financial assets, reduced R&D expenses, lower administrative expenses, and a decrease in fair value losses on financial liabilities [1] Group 2 - Sanofi Pharmaceuticals-B's core products include STP705, STP707, and STP122G, with STP705 being the most advanced in development and expected to be the company's first commercial product by 2025 [2] - STP705 is a dual-target siRNA that simultaneously targets TGF-β1 and COX-2, and it is the first and only drug in the siRNA cancer treatment field to achieve positive Phase II clinical results. In the Phase II trial for basal cell carcinoma, the 180ug dosage group achieved a 100% complete clearance rate [2] - The company is expanding the indications for STP705, having initiated Phase II clinical trials for scars, Phase I clinical trials for adult abdominal liposuction, and Phase I clinical trials for liver cancer. Additionally, STP705 has received orphan drug designation for the treatment of cholangiocarcinoma and primary sclerosing cholangitis [2]

Core Viewpoint - 圣诺医药-B reported a significant reduction in losses for the six months ending June 30, 2025, compared to the same period in the previous year, despite no product sales revenue generated [1] Financial Performance - The company recorded a loss of $3.4 million for the six months ending June 30, 2025, compared to a loss of $43.5 million for the same period in 2024 [1] - The reduction in losses is attributed to decreased fair value losses on financial assets, reduced R&D expenses, lower administrative expenses, and decreased fair value losses on financial liabilities [1] Strategic Initiatives - The company is actively seeking global and regional partnerships for STP705 and STP707, evaluating collaboration opportunities for the GalAhead™ platform assets, and establishing strategic alliances to enhance development capabilities [1] - Efforts are focused on maximizing the potential of the pipeline while minimizing development risks through shared expertise and resources [1] - The company is in discussions with several venture capital funds to establish a new entity aimed at advancing its product pipeline while optimizing R&D expenditures [1] Future Outlook - The company aims to submit a New Drug Application (NDA) for STP705 as early as 2027, with commercial success dependent on positive clinical data, regulatory approval, and robust intellectual property protection [1] - The commercialization strategy includes detailed market access planning, development of necessary infrastructure, and building partnerships [1]